Literature DB >> 7915753

Absence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDS.

F Bissuel, L Cotte, M de Montclos, M Rabodonirina, C Trepo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7915753     DOI： 10.1093/infdis/170.3.749

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  7 in total

Review 1.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

2.  Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.

Authors:  J K Griffiths; R Balakrishnan; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

3.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

4.  Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability.

Authors:  M Jakir S K Pinjari; Rahul Somani; Ritu M Gilhotra
Journal:  Indian J Pharmacol       Date:  2017 Jul-Aug       Impact factor: 1.200

Review 5.  Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Authors:  Anke E Kip; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

Review 6.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

Review 7.  Review article: the therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome.

Authors:  C M Wilcox; K E Mönkemüller
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.